Debiopharm
Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments
March 1, 2021Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant
German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …
Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment
October 21, 2016Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …
Debiopharm and Yale University to develop autoimmune treatment
May 5, 2011Research and Development Debiopharm, Yale University
Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …
Pfizer signs ‘personalised’ cancer collaboration
January 15, 2010Research and Development Cancer, Debiopharm, Pfizer, melanoma, skin cancer, tremelimumab
Pfizer is to co-develop its monoclonal antibody treatment for advanced melanoma with Swiss company Debiopharm. The companies will conduct phase …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
